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Abstract 
Heterocycles play an essential role in modern pharmaceutical and agrochemical 
developments, representing a very common
 
structural unit in marketed drugs. Over the 46 
new drugs approved in 2017 by the FDA, 25 contain in their structure an heterocyclic core. 
The development of novel and straightforward labeling strategies for the effective insertion of 
carbon isotopes into heterocylic scaffolds is an inspiring and vibrant field of research. The use 
of carbon-11, carbon-13 and carbon-14 isotopes is well established in life science and 
particularly in pharmaceutical and agrochemical industry. Their introduction into small 
organic molecules represents a crucial step for the radiochemists. Since the labeling should 
occur in metabolically stable positions and in the shortest synthetic route, their incorporation 
into the heterocycles represent a viable solution. This review summarizes recent contributions 
to this area of research through the analysis of different industrial and academic cases. 
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Introduction  
 
Heterocycles play an essential role in modern pharmaceutical and agrochemical 
developments, representing very common
 
motif in marketed drugs and in the drug discovery 
process
1
: over 80% of top small molecule drugs by US retail sales in 2010, contained at least 
one heterocyclic fragment in their structures
2
. In 2017, the FDA approved 46 new drugs, the 
highest total in more than two decades. Remarkably, 25 of such new molecules contain in 
their structure an heterocyclic moiety.
3
 Carbon isotopes (carbon-11, carbon-13 and carbon-14) 
are ideal tools for the labeling of small organic molecules allowing the traceless insertion of a 
mass or a radioactive tag without modifications of their properties and activity. Their efficient 
insertion of such labels into heterocycles has been a major challenge over the years. Synthetic 
access to heterocycles is generally well established in organic chemistry, but its 
implementation to carbon isotope labeling is often complicated by the different specifications 
of each radionuclide, notably the half-life and the fundamental sources of the isotope. Despite 
sharing the same reactivity, the three isotopes of carbon often requires specific strategies, with 
different challenges and diverse outcomes. As a direct consequence, the synthesis must be 
revisited and optimized in order to meet such strict requirements.  
In this review, the recent developments in heterocycles labeling with carbon isotopes are 
described, focusing on methods that allow the incorporation of the isotope within the 
heterocyclic scaffold. Due to the large amounts of publications reported in the literature, the 
authors decided to select recent works describing the most general and straightforward 
approaches. We apologize for those brilliant pieces of work that could not be included in the 
manuscript. 
 
Synthesis of 
11
C labelled heterocycles 
 
Positon emission tomography (PET) is a non-invasive molecular imaging technique used to 
study and visualize human physiology by the detection of positron-emitting 
radiopharmaceuticals
4
. Carbon-11 is a short-live positron-emitting radionuclide (t1/2 = 20.4 
min)
 5
 and radiotracers labeled with 
11
C are widely used for the early diagnosis of cancer, 
monitoring therapeutic response to cancer treatment, and pharmacokinetic investigations of 
anticancer drugs
6
. However, the narrow half-life window make high-specific-activity 
radiopharmaceuticals labeled with carbon-11 some of the most synthetically challenging to 
prepare. One major 
11
C-precursor utilized in synthesis is [
11
C]CO2 (the other being 
[
11
C]CH4)
7
. To date the most frequently used method for the introduction of 
11
C into organic 
molecules the methylation
8
. Methylations with this isotope are limited to the labelling of 
molecules at functional groups at peripheral atomic positions. Hence, alternative labelling 
pathways are mainly pursued when the target molecule does not contain a suitable functional 
group for methylation or if rapid in vivo metabolism of the tracer forces other atomic positions 
to be investigated
9
. 
Hit and lead small molecules and drugs often contain an heterocycles core in their structure, 
for these reasons new strategies to selectively introduce carbon-11 are highly desirable.  
The chemistry of carbon monoxide is well established and metal catalyzed carbonylation 
reactions have been widely explored. However, radiochemistry using [
11
C]CO presents 
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unique challenges that are not encountered with regular carbonylation reactions
10,11
. 
Traditionally, carbonylations are performed at elevated pressures and temperatures, with 
extended reaction times (typically >12 h) in order to improve the poor solubility of CO in 
common organic solvents and so maximize chemical yields. The short half-life of this isotope 
precludes such long reaction times and the miniscule amounts of isotopically labelled 
[
11
C]CO result in very low partial pressures, which disfavor its solubility and reactivity. [
11
C]-
carbon monoxide is therefore challenging both in terms of handling and reactivity
12
. In the 
next section, the more recent methods utilizing [
11
C]CO in metal catalyzed ring closure as late 
stage labelling procedure are emphasized. 
 
Metal catalyzed carbonylation  
Originally developed by Heck in 1974
13,14
, the palladium-catalyzed carbonylation has been 
used to access to a broad range of carbonyl-containing heterocycles such as 
benzoimidazolone, lactones, lactams etc., moieties widely spread in drug scaffolds and 
bioactive molecules. As previously mentioned, a major drawback of carbon monoxide is its 
poor solubility in organic solvent. A number of innovative solutions have been described to 
overcome this limitation, such as the use of the high-pressure method (i.e. performing the 
reaction in autoclave reactors)
15
 increasing mass transfer between the gas and liquid phases by 
expanding the interfacial contact area, by means of microfluid reactors and packed tube 
reactors. Another solution consists in its chemical trapping, in order to catch the carbon 
monoxide generated. In 2004, a BH3
.
THF solution was used to trap [
11
C]-carbon monoxide at 
room temperature in the form of a borane adduct. More recently, a copper (I) scorpionate 
complex, with a tris(pyrazolyl)borate ligand, has been used as efficient [
11
C]CO trapping 
agents. The tridentate geometry of the ligand leaves the metal center with a vacant 
coordination site for the interaction of carbon monoxide. This method has proven to give 
higher and more reliable trapping efficiencies than the borane one, in addition to its technical 
simplicity
16
.
 
Following the trapping procedures, palladium-mediated carbonylation reactions 
were performed to assemble a M1 muscarinic acetylcholine receptor radiotracer. [
11
C]-
GSK1034702 has been synthetized from the aniline precursor 1 by ring closure of a substitued 
benzoimidazolone
17
 (SCHEME 1a). From an experiment point of view, the [
11
C]-carbon 
monoxide/helium stream mixture was passed through a toluene solution containing the copper 
catalyst; meanwhile, the carbonylation coupling reagents (catalyst, aniline 1 and DMF) were 
heated in a separate vial at 100 °C for 5 min. Following [
11
C]CO delivery, the carbonylation 
reagents were injected into the vial and the vessel was sealed and heated (typically at 120 °C) 
for 5 minutes, obtaining the desired radiotracer with the radiochemical yield of 6%.
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SCHEME 1 a) Synthesis of M1 muscarinic acetylcholine receptor radiotracer [
11
C] 
GSK1034702 and b) [
11
C]-MK-0233; CuTp = copper (I) scorpionate complex. 
 
 
The mechanism of the palladium(II)-catalyzed oxidative carbonylation reaction is thought to 
proceed via formation of an isocyanate intermediate from a palladium carbamoyl species, 
which subsequently reacts with a free amine molecule (either primary or secondary) to 
generate the urea. Because secondary amines are unable to form isocyanates, tetrasubstituted 
ureas cannot form.
 
By means of a similar strategy, S. Kealey et al. reported the labeling of lactone [
11
C]-MK-
0233, a ligand for the neuropeptide Y5 receptor (SCHEME 1b)
18
. 
T. Cornilleau et al. described in 2015 the use of this carbonylative strategy to develop a last 
stage labeling of biomolecules. The authors conceived a general intermediate 3 bearing an 
alkyne moiety which could be easily functionalized by means of the notoriously famous 
copper catalyzed alkyne azide cycloaddition (CuAAC)
19
 with a variety of biomolecules. The 
triazole derivatives were further utilized for the insertion of a carbon isotope tag and 
formation of the desired five membered lactone [
11
C]-4. This strategy was successfully 
validated on a large variety of examples with carbon-13. A proof of concept with carbon-11 
was obtained on two representative substrates 3a and 3b that were labeled with high 
radiochemical purity, showing the high chemo selectivity and robustness of the carbonylation 
(SCHEME 2)
20
. 
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SCHEME 2 Last step labeling of biomolecules with [
11
C]CO via palladium catalysis.
 
 
Recently, a novel 
11
C-carbonylation protocol has been developed by Eriksson et al., which 
exploits the high solubility of xenon gas in organic solvents as an effective way of transferring 
the radioactive gas to a small volume reaction vial. The use of xenon as a delivery gas allows 
for quantitative transfer of carbon monoxide from a silica pre-trap into tiny amount of solvent 
volumes without significant xenon pressure build-up. This method is particularly attractive 
because it avoids the use of additional chemical trapping reagents or of a high-pressure micro-
autoclave. Moreover the system has been used for both palladium and rhodium 
11
C-
carbonylative coupling reactions to generate a series of simple amides, ureas and esters
21
.  
 
Rhodium is a catalytically active transition metal, used to perform a wide variety of C–C bond 
forming reactions
22
. Although rhodium-catalyzed carbonylation reactions are exploited in 
both industry and academia, their application in the synthesis of fine chemicals is less 
extensive than palladium. Rhodium-mediated reactions are generally performed between an 
azide and either an amine or an alcohol to form 
11
C-carbonyl labeled ureas and carbamates. 
As reported by J. Veerbek et al. this protocol was successfully applied to the cyclization of 6 
into [
11
C]-phenytoin in 22% RCY (SCHEME 3)
23
. 
 
 
SCHEME 3 Synthesis of [
11
C]-phenytoin via rhodium-catalyzed cyclization. 
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Metal - free carbonylation  
 
Besides [
11
C]-CO, another reagent utilized to introduce labelled-carbonyl moieties in 
heterocycles is [
11
C]-phosgene. First reported in the 1970s, the reactivity of [
11
C]-COCl2 is 
well-established and allowed the insertion of a labeled carbonyl between two heteroatoms 
without the need for dehydration, redox operations or transition metal catalysis
24
. 
A variety of 
11
C-carbonyl containing heterocycles are directly accessible using labelled 
phosgene, including imidazolones, oxazolidinones and an oxazolidindione. Among the 
earliest applications, the labeling of urea (by treatment with aqueous ammonia), a valuable 
precursor to labeled barbituric acids and nucleosides such as thymidine. Similarly, symmetric 
[
11
C]-carbonates and [
11
C]-ureas are readily prepared from [
11
C]-phosgene, as well as the 
heterocycles hydantoins and imidazolones (SCHEME 4)
25,26
. 
 
 
SCHEME 4 Radiolabeling using [
11
C]-phosgene. 
 
One selected example highlighting of the use of phosgene as effective tool for the 
radiosynthesis is depicted in SCHEME 5. Compound [
11
C]-8, a PET radiotracer studied for 
imaging NR2B containing NMDA receptors, was obtained from the corresponding o-
phenylenediamine (7) in 30-40% RCY
27
.
 
 
 
SCHEME 5 Synthesis of PET radiotracer [
11
C]-8.
 
 
Despite its remarkable reactivity, [
11
C]-phosgene requires the utilisation of specialized 
apparatus and a complicated production, thus limiting a broad utilization. [
11
C]-carbon 
dioxide, is a highly convenient reagent in radiolabeling: its direct utilization and its 
functionalization to more reactive synthons are indeed highly desirable. 
7 
 
In 2012, Schou et al. reported the conversion of labelled carbon dioxide directly in the 
formiate [
11
C]-9 using lithium triethylborohydride, as reducing agent; subsequent reaction in 
presence of bidentate nucleophiles, such as benzene-1,2-diamine, allowed the formation of the 
corresponding benzimidazole [
11
C]-11 in 96 % radiochemical purity 
28
 (SCHEME 6).  
 
 
SCHEME 6 General preparation of [
11
C]-11.
 
 
Similarly to CO, carbon dioxide is poorly soluble in polar organic solvents. It has been shown 
that the utilization of organic nitrogenous bases such as BEMP or DBU help the fixation of 
radiolabeled CO2 in DMF and other polar solvents
29,30
.  
Two examples were recently reported from Mossine et al.
31
 where new radiotracers 
containing cyclic urea rings were synthetized using CO2 fixation. [
11
C]-QZ, a radiotracers for 
glutaminyl cyclase (QC) and glycogen synthase kinase-3 (GSK-3), was obtained from the 
amine precursor 12 and POCl3 as dehydrating agent. The intermediate isocyanate, formed in 
the sequence, was immediately trapped to obtain the final compound in 1% RCY. 
The same conditions were used for the radiotracer [
11
C]-Tideglusib, an inhibitor of GSK-3. In 
this example the isocyanate [
11
C]-14 was reacted with benzyl isothiocyanate and subsequently 
underwent ring formation obtaining the final drug in 2% RCY (SCHEME 7).  
 
 
SCHEME 7 Synthesis of [
11
C]-QZ a PET radiotracer for glutaminyl cyclase, and the inhibitor 
of glycogen synthase kinase-3 [
11
C]-Tideglusib. 
 
In 2015, the Miller group reported a rapid and high yielding route to carbon-11 labeled carbon 
disulfide. This methodology shows many of the desirable characteristics for PET labeling: 
ease of synthesis and handling, high reactivity and the potential to radiolabel a wide range of 
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compounds
32
. [
11
C]CS2 is obtained directly from radiolabeled methyl iodide, where the gas 
phase is reacted with phosphorus pentasulfide P2S5 at 380 °C and then collected in an 
acetonitrile solution
33
. 
From a reactivity standpoint, carbon disulfide is a good electrophile with relatively weak C=S 
double bonds, comparably more reactive than carbon dioxide. Most of the fine chemicals 
obtained using this synthon belong to the thiourea family, known precursors heterocyclic 
structures. A notable example is the efficient late stage labeling of [
11
C]-Tanaproget, a 
progesterone receptor agonist, which was achieved from the corresponding aniline precursor 
15 in 14% RCY
34
 (SCHEME 8). 
 
 
SCHEME 8: Radiosyntheis of progesterone receptor agonist [
11
C]-Tanaproget.  
 
As highlighted here, carbon-11 labeling of heterocycles still represent a monumental 
challenge today. The methods available are rather limited and carbonylative cross coupling 
are the most effective tool reported so far. We believe there is still ample room for 
improvement and methodologies favoring the use of [
11
C]CO2 might be encouraged. 
 
Synthesis of 
14
C labelled heterocycles 
 
Carbon-14 is a long-lived radioactive isotope of carbon (half-life 5730 years) which has been 
exploited for decades in a wide range of applications, especially in life sciences, including 
research and development of pharmaceuticals and crop protection agents.
35
  
While compounds labeled with tritium are used during basic research studies, carbon-14 
labeling is an ideal tool for in vitro and in vivo characterization of adsorption, distribution, 
metabolism ad excretion (ADME) in animals and humans, due to its resistance to metabolic 
cleavage
36,37
.
 
Unfortunately, the introduction of this radioisotope into organic molecules often 
requires harsh and multi-step synthetic procedures from the most readily accessible sources of 
the isotope: [
14
C]-barium carbonate, [
14
C]-carbon dioxide and [
14
C]-potassium cyanide  
 
An interesting example of heterocyclic labelling with carbon-14 was reported in 2014 by 
Barrel and co-workers for the synthesis of [
14
C]-Avagacestat, a γ-secretase inhibiting drug 
reported by Bristol-Meyer-Squibb for the treatment of Alzheimer disease
38
. In this multi-step 
synthesis, the carbon label was introduced in the very beginning by a palladium-mediated 
cross coupling reaction between 4-bromo-2-fluorotoluene (16) and [
14
C]-Zn(CN)2, 
synthetized in one quantitative step from [
14
C]-KCN (SCHEME 9)
39
. The nitrile derivative 
[
14
C]-17 was readily converted in to the corresponding hydroxylamine [
14
C]-18, which was 
9 
 
subsequently cyclized in presence of boron trifluoride and trimethyl orthoformate, affording 
the desired labelled 1,2,4-oxadiazole derivative [
14
C]-19. In three additional steps, [
14
C]-19 
could be converted into the labeled Avagacestat with 13.77 mCi produced. 
 
 
SCHEME 9 Synthesis of carbon-14 labeled Avagacestat. 
 
The 1,2,4-oxadiazole core is found as well in compound [
14
C]-24, known as BI665915, a 
novel 5-lipooxigenase (FLAP) inhibitor developed in 2015 by Boehringer Ingelheim for the 
treatment of inflammatory diseases
40
. Palladium catalysed cyanation in presence of carbon-14 
zinc cyanide allowed to obtain pyrazole [
14
C]-21 in 90%. The carboxylic acid [
14
C]-22 was 
obtained by hydrolysis of derivative [
14
C]-21 using NaOH, while the following step allowed 
to assemble the [
14
C]-oxadiazole core of the drug ([
14
C]-23). The key cyclization was 
achieved through the activation of the carboxylic acid with carbonyldiimidazole (CDI) in 
presence of oxime 22a, three additional steps were required to deliver the desired [
14
C]-
labeled oxadiazole with 84% yield and 20.5 mCi produced (SCHEME 10). 
 
  
SCHEME 10 Synthesis of carbon-14 BI665915. 
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The imidazole core is another ubiquitous motif present in drugs. Easter and co-workers 
recently reported the access to [
14
C]-Declatasvir, an intriguing example of symmetric 
imidazole containing drug
41
 (SCHEME 11). 
 
 
SCHEME 11 Structure of [
14
C]-declatasvir. 
 
This compound, commercialized by Bristol-Meyer-Squibb under the name of Daklinza, is an 
inhibitor of NS5A, a multifunctional protein involved in the replication of Hepatitis C virus. 
Its synthesis starts with the introduction of carbon-14 labeled CN on 4,4’-dibromodiphenyl 
(25), in refluxing DMF affording the diphenil-4,4’-dicarbonitrile [14C]-26 in 91% yield. 
 
SCHEME 12 Synthetic approach to symmetric imidazole derivative [
14
C]-29. 
 
The nitrile
 
function was further converted to the corresponding diacetylbiphenyl [
14
C]-27 
using a tert-butyldimethylsilyl chloride-promoted nucleophilic addition of methyl magnesium 
chloride to the nitrile, in presence of a catalytic amount of copper bromide in 51% yield
42
. 
Subsequent bromination and treatment with Boc-L-proline afforded the chiral precursor [
14
C]-
28, that was readily cyclized in presence of NH4OAc in refluxing toluene. Two additional 
steps yielded the desired [
14
C]-Declatasvir (SCHEME 12). 
In 2016, Shockravi et al. reported the synthesis of [
14
C]-33, a selective COX-2 inhibitor 
belonging to the class of NSAID’s (nonsteroidal-anti-inflammatory drugs). In this case, 
11 
 
benzyl cyanide [
14
C]-31 was obtained in good yield from benzyl chloride 30 and the readily 
available [
14
C]-KCN. After three additional steps [
14
C]-31 was elaborated into the α-bromo-
carbonyl derivative [
14
C]-32
43
. In presence of sodium methoxide [
14
C]-32 was further 
converted into the α-hydroxy-carbonyl [14C]-32a, then the crude material was directly treated 
with NH4SCN in refluxing n-butanol, affording the labeled thiourea [
14
C]-33 with 46% of 
overall yield (SCHEME 13). 
 
SCHEME 13 Synthesis of carbon-14 labeled thiourea derivative 33. 
 
An expedient to label thiourea and thiopyrimidine heterocycles was described by Hickey et al. 
for the realization of [
14
C]-AZD-5122, a compound under evaluation as CXCR2 antagonist, a 
receptor involved in the accumulation and activation of neutrophils to the inflammations 
sites
44
. The isotope was introduced in to the pyridine ring using [
14
C]-thiourea, which was 
condensed with diethyl malonate to afford the corresponding [
14
C]-thiobarbituric acid salt 
[
14
C]-34. In this way, the radioisotope was inserted in to a metabolically stable position, 
forming a six membered ring heterocycle with a masked thioguanidine. Further elaboration 
enabled the access to the desired [
14
C]-AZD-5122 in 67% yield with 18.9 mCi produced 
(SCHEME 14). 
 
SCHEME 14 General approach to the synthesis of carbon-14 AZD5122. 
 
In 2014, Elmore and co-workers at AstraZeneca reported a straightforward synthesis of [
14
C]-
oxazole [
14
C]-38. This spiro compound was required to investigate DMPK properties in a 
12 
 
research program aiming towards the development of α7 agonists for the treatment of 
Alzheimer disease. [
14
C]-nicotinic acid was prepared from 3-bromopyridine 35, treated first 
with BuLi at -70 °C and further quenched with [
14
C]CO2, with 58% of yield
45
. A peptide 
coupling between the elaborated amine 36 and [
14
C]-nicotinic acid gave the corresponding 
amide [
14
C]-37 in 40% yield. The key cyclization was performed heating the amide neat with 
the Eaton’s reagent (7.7 wt% P2O5 in MeSO3H) at 130 °C affording the desired oxazole [
14
C]-
38 in 33% of yield and specific activity of 56 mCi/mmol. Though the yields of the synthesis 
are moderate, the α7 agonist could be assembled and labelled in only three steps from the 
most fundamental building block, [
14
C]CO2 (SCHEME 15). 
 
 
SCHEME 15 Synthesis of carbon-14 labeled α7 receptor agonist. 
 
2-Iminothiolane, also known as Traut’s Reagent46, is used as a tool to introduce a reactive 
thiol on a primary amine side chains of peptides. This lysine-thiolating agent has found 
applications as a linker in antibody-drug conjugates. (SCHEME 16)
47
. Wallace and co-
workers at Bristol-Myers Squibb published a 
14
C-radiosynthesis of this reagent in 2015. The 
isotope was introduced via SN2 reaction between [
14
C]-KCN and 1-bromo-3-cloropropane 
affording the radiolabeled derivative [
14
C]-39 with 82 % of RCY. The reaction with thiourea 
delivered the [
14
C]-isothiouronium hydrochloride salt [
14
C]-40, which was readily hydrolysed 
to compound [
14
C]-41. Under acidic conditions, [
14
C]-41 spontaneously cyclized to form 
[
14
C]-2-iminothiolane [
14
C]-43 with a RCY of 68% (SCHEME 16). 
13 
 
 
SCHEME 16 Synthesis of carbon-14 labeled Traut’s reagent. 
 
Deleobuvir is a non-nucleosidic selective NS5B polymerase inhibitor, marketed for the 
treatment of hepatitis C virus (HCV) infection. Its structure features two bicyclic 
heterocycles: a benzo-imidazole and an indole, connected to each other by a peculiar 
methylen-cyclobutan amide spacer. For its labeled version, Latli and co-workers decided to 
insert the radiocarbon tag on the benzoimidazole moiety
48
. The t-butyl cinnamate derivative 
44 was reacted in presence of acid chloride [
14
C]-49 affording the key labelled intermediate 
[
14
C]-45, a benzo[d]imidazolone which was readily coupled with the other portion of the 
scaffold bearing the indole derivative (46). Further saponification of the butyl ester delivered 
the final [
14
C]-Deleobuvir. The key cyclobutane amino acid [
14
C]-49 was obtained by means 
of a Bucherer-Bergs reaction in presence cyclobutanone 47, [
14
C]-KCN as radioisotope source 
and ammonium carbonate, to form the hydantoine intermediate [
14
C]-48 which was converted 
to compound [
14
C]-49 in two additional steps (SCHEME 17). 
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SCHEME 17 a) Synthesis of carbon-14 labeled Deleobuvir; b) synthesis of carbon-14 labeled 
cyclobutane amino acid. 
 
In 2015, the same authors described the carbon-14 radio synthesis of compound [
14
C]-55, a 
potent IκB Kinase-β (IKK-β) inhibitor. Interestingly the thienopyridine heterocycle is largely 
present in different classed of compounds, with a broad recognized activity as HCV 
inhibitors, allosteric modulator of M4 muscarinic receptor and inhibitors of NMDA 
receptors
49
. For the realization of the bicycle, the authors started from the synthesis of a 
14
C-
labeled pyridone using 2-cyanoacetamide [
14
C]-51 and a difluoroketoester 52. This 
Guareschi-Thorpe condensation in presence of DBU enabled the assembly of the 
corresponding tetrahydropyridine [
14
C]-53 which was further decorated to obtained compound 
[
14
C]-54 and cyclized under basic conditions to form the desired thienopyridine [
14
C]-55, 
ready utilized for ADME studies (SCHEME 18). 
 
15 
 
 
SCHEME 18 Synthesis of carbon-14 labeled IKK-β inhibitor. 
 
With the aim to develop a general approach to the synthesis of [
14
C]-benzooxazoles and [
14
C]-
benzothiazoles, Loreau and co-workers proposed a methodology based on the polarity 
inversion of the classic cyanating reagent KCN
50
. Electrophilic cyanide donor N-
cyanobenzotriazole (BtCN) was generated in situ by adding N-chlorobenzotriazole (Bt-Cl) at 
0 °C to [
14
C]-KCN. Labeled BtCN readily reacts with differently substituted 2-aminophenols 
or 2-aminothiophenol, affording in one pot the corresponding labeled heterocycles. This 
methodology was applied for the radio-synthesis of [
14
C]-56, an advanced intermediate for the 
realization of different (R)-aryloxypropionic acid derivatives, a class of compound with 
herbicidal activity. [
14
C]-56 was obtained via amide coupling with 45% RCY and 134.5 MBq 
produced. It is worth mentioning, this one-pot protocol minimize the number of purifications 
required, limiting the generation of radioactive wastes and reducing the overall costs of the 
synthesis (SCHEME 19). 
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SCHEME 19 General procedure for the synthesis of carbon-14 labeled aryloxypropionic acid 
amides precursor. 
 
In 2015, Latli et al. described the radiolabeling of pyrrole [2,3-c]pyridine from a [
14
C]-alkyne 
derivative [
14
C]-57, which was cyclized during the last synthetic step to form the desired 
glucocorticoid receptor antagonist [
14
C]-59
51
. In this approach, the radioactivity was 
introduced via a regioselective ring opening of the chiral oxirane 56 by the advanced and 
doubly labeled precursor [
14
C]-lithium (trimethylsilyl)acetylide. The silyl derivative was then 
treated with NaOH affording [
14
C]-57. Consequently the [
14
C]-labelled pyrrole[2,3-c]pyridine 
[
14
C]-59 was assembled from [
14
C]-58, in a single deprotection and cyclization step, to form 
the final compound with no configurational changes (SCHEME 20). 
 
 
SCHEME 20 Synthesis of carbon-14 labeled glucocorticoid receptor antagonist. 
 
Recently, the labeling of the condensed heterocycle [
14
C]-61 was reported in a study by the 
Tran’s group. This unconventional scaffold is present in a library of CB-1 antagonists, a class 
of compounds under investigation for the treatment of obesity
52
. The main core of the 
molecule, a triazolo [4,3-b] pyridazine carrying a carbonyl in position 2, was labeled 
quantitatively via a metal free carbonylation using [
14
C]-CDI. (SCHEME 21) 
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SCHEME 21 General synthetic route to carbon-14 labeled core of CB-1 receptor antagonist. 
 
Omarigliptin, a compound currently in use for the treatment of diabetes mellitus type 2, was 
radiolabelled in 2016 by the Hesk group on the pyrazoles ring. Once more the use of 
hydrazine proved fundamental for the synthesis of condensed heterocycles
53
. In this case, the 
synthesis previously developed by the medicinal chemistry group was not viable and the 
radiochemists at Merk had to develop a whole new approach. The source of radioactivity 
chosen in this strategy was [
14
C]-sodium formate, which was reacted in presence of biphenyl 
precursor 62 to give the corresponding formate [
14
C]-63. A Claisen condensation with the 
enantio pure ketone [
14
C]-64 in presence of tBuOK afforded the corresponding vinylogous 
acid [
14
C]-65 in 62% yield. Another condensation with hydrazine delivered the desired 
bicyclic key scaffold ([
14
C]-66) in one pot with the 94% of yield and 6.6 mCi of material 
produced (SCHEME 22). 
 
 
SCHEME 22 General synthesis of carbon-14 labeled Omarigliptin. 
 
In 2014, chemists at Perkin Elmer realized a labelled version of Bergapten
54
, a compound 
belonging to furocoumarin family, bearing the 
14
C atom in the pyrone ring, specifically at 
position 7. The previously reported synthesis of unlabelled Bergapten, starting from the 
aldehyde 68 and [
14
C]-malonic acid, was not suitable to carbon labeling due to the required 
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large excess of radioactive malonate. In addition, the following decarboxylation would have 
resulted in dilution of the specific activity and partial loss of the label. For those reasons, the 
authors decided to use a different strategy, based on the Wittig olefination of 68 in presence of 
the stabilized [
14
C]-phosphonium ylide. The corresponding olefine was further cyclized at 220 
°C in N,N-dimethyl aniline affording [
14
C]-labelled Bergapten with 47% of RCY (SCHEME 
23). 
 
SCHEME 23 General approaches to the synthesis of carbon-14 labeled Bergapten. 
Thioxanthen-9-one is a common scaffold present in several drugs with anti-parasitic activity, 
such as Lucanthone, a compound that exhibits anticolinergic activity in worms, in use for the 
treatment of schistosomiasis. In 2016, Javaheri et al. described a general route to such a 
tricyclic core
55
.The synthesis starts with the reaction between anthranilic acid [
14
C]-69, 
readily obtained from [
14
C]-potassium cyanide. Compound [
14
C]-69 was solubilized in water 
and concentrated HCl, then a solution of sodium nitrite was gradually added, at temperatures 
below 5 °C. The intermediate labelled diazo derivative was added to a Na2S2 solution. The 
resulting dimeric [
14
C]-dithiosalicylic acid [
14
C]-70 was precipitated and subsequently 
refluxed in AcOH in presence of metal Zn, to afford the monomer [
14
C]-71. Further 
condensation with p-fluorotoluene under acidic conditions afforded the [
14
C]-labeled 
thioxanthene as mixture of regioisomers [
14
C]-72, [
14
C]-73, in 66% combined yield 
(SCHEME 24). 
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SCHEME 24 Synthesis of carbon-14 labeled thioxantene. 
 
Tricyclic heterocycles are largely found in drugs with antipsychotic activity. Olanzapine, 
commercialized by Eli Lilly under the name of Zyprexa, is a representative example
56
. The 
carbon-14 radio synthesis of this particular second-generation neuroleptic agent starts from
 
a 
nickel-catalysed cyanation of 3-bromo thiophene 74, according to a previously reported 
procedure
57
. Subsequent nitro group reduction, followed by Buchwald-Hartwig cross coupling 
with 1-bromo-2-iodobenzene and N-methyl piperazine addition to the nitrile, afforded the key 
precursor [
14
C]-76. [
14
C]-Olanzapine was finally obtained by an intramolecular metal 
catalysed cross coupling reaction in a 40% of isolated yield with 11.6 MBq produced 
(SCHEME 25). 
 
 
SCHEME 25 Synthesis of carbon-14 labeled Olanzapine 
 
As highlighted in this section, a very large variety of carbon-14 labeled heterocycles can be 
prepared. Unfortunately, most of the current approaches are lengthy, multi-step and demand 
massive efforts in terms of time and resources. Given the importance of this isotope and its 
implications in life science, future developments should favor the late and last stage carbon-
14 labeling of heterocycles using the simplest sources of the isotope (*CO2, *CO and *CN). 
 
Synthesis of 
13
C labelled heterocycles 
Carbon-13, a natural abundant stable isotope of carbon (1.1%), is a valuable tracer in 
chemical, biological and environmental science. Common implications in mechanistic 
investigations in synthetic organic chemistry and its impact on NMR spectroscopy are well 
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known
58
.The recent developments of dynamic nuclear polarization (DNP), which dramatically 
increases the sensitivity of the [
13
C]-MRS experiment (>10,000 times) has allowed real-time 
imaging of several substrates and the metabolites formed from them in vivo
59
. In 2018, La 
Clair has suggested a novel implication of this isotope for the encryption of materials, by 
adjusting the levels of [
13
C] at regiospecific atoms within a molecule, to generate a stable-
isotopically encoded signature
60
. It is worth mentioning that in stark contrast to the carbon-11 
and carbon-14, the fundamental source of this isotope is carbon monoxide, as the current 
world production of 
13
C is based on the cryogenic distillation of carbon monoxide
61
. 
Over the last decade, tremendous efforts from the group of Prof. T. Skrydstrup in Denmark on 
the development of novel carbonylation strategies were made. In order to prevent the handling 
of poisonous CO gas, this group developed a novel two-chamber reactor, which allows the ex 
situ generation of carbon monoxide (first chamber) which is subsequently delivered in the 
second chamber for its incorporation into complex organic molecules by means of metal 
catalyzed carbonylation reactions. The ex situ generation of CO was triggered by a palladium 
catalyzed decarbonylation of tertiary acid chloride (COgen) using palladium catalysis under 
mild conditions. This two chamber glassware system is known as Coware and is 
commercially available
62 
(SCHEME 26). Besides Cogen, the same group reported the 
generation of carbon monoxide using silyl derivate 
63
 starting directly from CO2. 
64
 By 
enabeling a safe handling of carbon monoxide, this technology had a massive impact on the 
field of metal catalyzed carbonylations. Subsequent elaboration of these carbonyl containing 
derivatives afforded a large variety of [
13
C]-labeled heterocyles. It is worth noting that novel 
developments in the field of [
13
C]-carbonylation can be highly inspiring and relevant for 
carbon-14
65
. 
 
 
SCHEME 26 General formation of CO inside Cogen.
 
 
Palladium catalyzed intramolecular aminocarbonylation was shown to be a powerful tool for 
the direct labeling of heterocycles. Lactame [
13
C]-78 was successfully obtained in 75% yield 
while the seven membered dibenzoxazepine ring [
13
C]-80 could be isolated in 80% yield. 
Compound [
13
C]-78 is a precursor of Loxapine, an antipsychotic, used primarily in the 
treatment of schizophrenia (SCHEME 27a).
62
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SCHEME 27 a) Intramolecular aminocarbonylation forming six and seven member ring; b) 
approach to benzoxazoles via aminocarbonylation and acidic ring closure.
 
 
 
A few years later, the same group published a sequential one-pot protocol for the synthesis of 
functionalized benzoxazoles (SCHEME 27b)
66
. Aminocarbonylation of aryl and vinyl 
bromides (81) with 2-aminophenols (82) followed by an acid mediated ring closure generated 
the benzoxazole heterocycles 84. The methodology displays a broad substrate scope and 
generally good yields. This carbonylative protocol was successfully applied to the synthesis of 
a potential Alzheimer’s plaque binder [13C]-BF-168 and [13C]-JTP426467, a selective PPAR 
antagonist. The synthesis of this last compound includes also a site-specific double 
incorporation of [
13
C]-carbon monoxide. 
In 2011, the same authors reported a carbonylative Heck reaction between aryl iodides (90) 
and styrene derivatives (91) that efficiently delivered ,β-unsaturated ketone ([13C]-92). 
Interestingly, compound [
13
C]-92 was directly converted under acidic conditions into the 
corresponding indanone [
13
C]-93 in 74% yield (SCHEME 28)
67
.
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SCHEME 28 Approach to Indanone scaffold via carbonylative Heck reaction.  
 
The subsequent year, the group of Skrydstrup disclosed the formation of 1,3-diketones 
through palladium-catalyzed carbonylative -arylation of ketones with aryl iodides. It is well 
known that 1,3-diketones are privileged precursors to access a large variety of heterocycles 
68
. 
The authors explored the possibility of using their novel transformation for the isotopic 
labeling of three fundamental heterocyclic scaffolds largely found in medicinal chemistry: 
pyrazole, isoxazole and flavone. 2-iodophenols 94a-b were carbonylated in excellent yields 
using carbon-13 labeled COgen. Subsequent hydrolysis of the methoxymethyl ether [
13
C]-96a 
and cyclization formed the flavone [
13
C]-97 in quantitative yield. Derivative [
13
C]-96a was 
converted into the corresponding pyrazoles [
13
C]-98 and isoxazole [
13
C]-99, under standard 
conditions in presence of hydrazine and hydroxylamine respectively (SCHEME 29). These 
examples highlighted the effectiveness of carbonylative cross coupling for the late stage 
carbon labeling of relevant heterocycles, which are commonly found in drugs and natural 
products. It is worth noting that such scaffolds were obtained in only two steps using [
13
C]-
COgen. 
 
 
SCHEME 29 Sythesis of drug-like heterocycles via palladium catalyzed carbonylation.  
 
Another successful example of the two chamber COgen system in the context of heterocycle 
labeling was reported in 2014 by means of a palladium-catalyzed carbonylative coupling of 
(2-aza-aryl)methyl anion equivalents with (hetero)aryl bromides. Under the optimized 
reaction conditions, (2-pyridyl)acetone (100) was converted into of aryl-2-(2-
pyridyl)ethanone in one single operation. Derivative [
13
C]-102 was isolated 85% yield 
(SCHEME 30)
69
. 
 
Benzylic bromination followed by reaction with thiourea resulted in the 
formation of the disubstituted thiazolamine [
13
C]-103 in a 58% yield. The reaction of [
13
C]-
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102 with hydroxylamine followed by sequential treatment with trifluoroacetic anhydride and 
iron(II) chloride delivered the isotopically labeled pyrazolopyridine [
13
C]-104 in a 46% yield. 
 
 
SCHEME 30 Carbon-13 labeling of thiazolamine and pyrazolopyridine derivatives. 
In the same year, the Skrydstrup group expanded even further the scope of heterocycles with 
benzothiophene,
70
 1,2,4- and 1,3,4-oxadiazole derivates
 71
. In the first report, the aryl bromide 
105 was coupled with 2- mercaptobenzophenones 106 via palladium carbonylation in order to 
obtain the thioester [
13
C]-107 with 70% yield; then under McMurry coupling conditions the 
thioester was cyclized to obtain [
13
C]-108 in good yield, as depicted in SCHEME 31. 
 
SCHEME 31 Synthesis of benzothiophene derivate via palladium carbonylation and 
McMurry coupling.
 
Another remarkable application was described in 2014 on the formation of substituited 1,3,4-
oxadiazoles. In the two step procedure depicted in SCHEME 32a, a variety of (het)aryl 
bromides (109) were coupled with hydrazide derivates (110) under the carbonylating 
condition and the cyclization were performed in one pot with good to excellent yields. 
Moreover, another regioisomer of this scaffold could be labeled, the 1,2,4-oxadiazole, leading 
to the pharmaceutical relevant compound [
13
C]-Ataluren, a drug used for the treatment of 
Duchenne muscular dystrophy. In SCHEME 32b is depicted the synthesis of [
13
C]-Ataluren, 
obtained with a coupling between the amidoxide 113 and fluoro aryl bromide 112. 
 
24 
 
 
SCHEME 32 a) formation of subsostituited 1,3,4-oxadiazole; b) Synthetic approach to [
13
C]-
Ataluren, 1,2,4-oxadiazole. 
 
Very recently, Skrydstrup reported the synthesis of THK-523, a pharmaceutically relevant 
Tau binder (SCHEME 33)
72
. This compound was obtained through a palladium catalyzed 
carbonylative Sonogashira coupling ([
13
C]-117, 72%) and a subsequent reductive cyclization 
step with hydrogen or deuterium gas ([
13
C]-THK-523, 87%). Though this is not a direct late 
stage carbon labeling, however this and the previous methodology display an high potential 
for the carbon labeling of a large number keys heterocycles in natural products and drug-like 
molecules.  
 
 
SCHEME 33 Synthesis of pharmaceutically relevant Tau binder [
13
C]-THK-523. 
 
Metal catalyzed carbonylative cross coupling reactions are very effective tools to access a 
large number of heterocycles. This section clearly highlights the potential of this reaction. In 
principle, this chemistry could be fully adapted to carbon-14 labeling as well. To our surprise, 
for the moment it has not been the case. One possible explanation is that 
14
C-Cogen requires a 
three steps process to generate [
14
C]CO and might discourage its popularization in the 
radiochemical community. Transformations leading to the formation of labeled CO directly 
from CO2 might be beneficial to broaden its utilization in radiochemistry. 
Conclusions and outlook 
In this review, we have presented on overall view of the recent advances in the context of 
carbon isotope labeling of pharmaceutically and agrochemically relevant heterocycles. This 
exciting field is nowadays very rich and vibrant as highlighted by the variety of solutions 
reported in the last five to ten years. Despite such great number of approaches, as a matter of 
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fact, this topic is today still very challenging and the available synthetic solutions are often 
substrate specific and lack of generality. Of course, one major limitation is related to the 
different specifications of carbon isotopes and general solutions have so far not been reported. 
From an ideal point of view, the development of new methodologies utilizing the most simple 
labeled starting materials (*CO2, *CO, K*CN), short reaction times and late or last stage 
labeling should be favored in the future. When possible, these guidelines should be kept in 
mind. We are very confident that the carbon isotope labeling can provide a whole range of 
innovation in the next decades.  
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